SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 2001
-----------------
EDG Capital, Inc.
-----------------
(Exact name of registrant as specified in its charter)
New York 33-37674-NY 11-3023098
-------- ----------- ----------
(State or other (Commission File Number) (IRS Employer
jurisdiction of Identification No.)
incorporation)
700 Stewart Avenue, Garden City, New York 11530
-----------------------------------------------
(Address of principal executive offices, zip code)
Registrant's telephone number, including area code: (516) 222-7749
--------------
N/A
---
(Former name or former address, if changed since last report)
Item 5. Other Events.
On February 13, 2001, EDG Capital, Inc. issued a press release announcing
that it is resuming clinical trials of Colloidal (32)P Phosphorus and
Macroaggregated Albumin (P32/MAA) in the treatment of brain cancer. As announced
earlier, the Food and Drug Administration ("FDA") had asked for assurances that
the P32 and MAA products meet a specific endotoxin purity requirement before
enrollment of patients into the brain cancer study could continue. The supplier
of these products has agreed to take the necessary steps that will enable the
company to comply with the FDA requirements.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 EDG Capital, Inc. Press Release issued February 13, 2001.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
EDG CAPITAL, INC.
Dated: February 13, 2001 By: /s/ Jack Schwartzberg
------------------------------------
Jack Schwartzberg
Chief Executive Officer, President
and Chairman
3